Due to the complexities involved with neurotrophin drug delivery, and the monogenic nature of HD, many compounds investigated within the HD clinical trial pipeline to date did not target BDNF or TrkB directly, but instead acted on mHTT expression itself. The gene discussed is BDNF; the disease is Huntington disease.